The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
03/01/2010
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Description of Modification
FOA has been amended to extend the Application Submission Receipt Date May 3, 2010, to allow for CDC to OPT-OUT with NIH, for 12 pages limit for activity code (U18).
Document Type:
Modification to Previous
Grants Notice
Funding Opportunity Number:
RFA-IP-10-007
Opportunity Category:
Discretionary
Posted Date:
Mar 01, 2010
Creation Date:
Apr 26, 2010
Original Closing Date for Applications:
Apr 26, 2010
Letter of Intent Receipt Date:
March 29, 2010
Application Submission Receipt Date:
April 26, 2010
Current Closing Date for Applications:
May 03, 2010
Letter of Intent Receipt Date:
March 29, 2010
Application Submission Receipt Date:
May 3, 2010
Archive Date:
May 26, 2010
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Health
Category Explanation:
Expected Number of Awards:
2
Estimated Total Program Funding:
$1,500,000
Award Ceiling:
$1,000,000
Award Floor:
$0
CFDA Number(s):
93.185
--
Immunization Research, Demonstration, Public Information and Education_Training and Clinical Skills Improvement Projects
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility:
Eligible Institutions
You may submit an application(s) if your organization has any of the following characteristics:
Public nonprofit organizations
Private nonprofit organizations
Universities
Colleges
Research institutions
Hospitals
Community-based organizations
Faith-based organizations
Federally recognized or state-recognized American Indian/Alaska Native tribal governments
American Indian/Alaska Native tribally designated organizations
Alaska Native health corporations
Urban Indian health organizations
Tribal epidemiology centers
State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau)
Political subdivisions of States (in consultation with States)
Foreign Institutions
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Attach this documentation behind the first page of your application form or for electronic applications, use a PDF file and attach as “Other Documents” and label as appropriate.
Agency Name
Centers for Disease Control and Prevention
Description
Current adult community acquired pneumonia (CAP) treatment guidelines recommend empiric broad-spectrum antibiotics that are effective against common bacterial agents. The initiation of antibiotics does not require laboratory confirmation of a bacterial etiology but is based upon data from published CAP etiology studies. Despite studies that have identified influenza as an important etiological agent of adult hospitalized patients with CAP, especially during peak influenza circulation, anti-influenza antiviral agents are uncommonly used empirically for CAP. In addition, novel influenza A (H1N1) has been documented to cause primary viral pneumonia in a majority of deaths with extensive testing of autopsy specimens. Most clinicians wait for laboratory confirmation of influenza infection before considering antiviral therapy. However, in routine clinical practice, diagnostic testing for influenza is uncommon, commonly used rapid testing methods have low sensitivity, and more sensitive diagnostic assays such as RT-PCR are not readily available. Also, even influenza RT-PCR assays performed on respiratory specimens are not always optimal for the detection of influenza infection and results of testing may take several days, after which the benefit if initiating antivirals goes down since the medications are of greatest benefit the earlier they are initiated after illness onset from influenza. Studies in Thailand have demonstrated that an additional 10-20% of acute influenza cases were identified with serologic assays, in addition to RT-PCR techniques on nasopharyngeal specimens.Thus, the use of empiric antiviral therapy, in addition to empiric antibiotic therapy, may be warranted, especially during a period when influenza viruses are circulating in the community.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
CDC Procurement and Grants Office
TIMS
Phone 770-488-2700
PGOTIM@cdc.gov
Synopsis Modification History
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.
